Completed PHASE2 INTERVENTIONAL 4-arm NCT02342249

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX 787 Administered as Monotherapy and One Dose Level of VX-787 Administered in Combination With Oseltamivir for the Treatment of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Sponsor: Janssen Pharmaceuticals

Conditions Influenza A

Interventions Oseltamivir 75 mg Placebo VX-787 300 mg VX-787 600 mg

Updated 10 times since 2017 Last updated: Jan 31, 2025 Started: Dec 11, 2014 Primary completion: May 25, 2016 Completion: May 25, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02342249, this PHASE2 trial focuses on Influenza A and remains completed. Sponsored by Janssen Pharmaceuticals, it has been updated 10 times since 2014, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Mar 2025 — Sep 2025 [monthly]

Completed PHASE2
Sep 2024 — Mar 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jul 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Feb 2017 — Jul 2017 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Pharmaceuticals
Janssen Research & Development, LLC

Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Advance, United States , Akron, United States , Alexandria, United States , Amarillo, United States , Anaheim, United States , Anderson, United States , Arlington, United States , Athens, United States , Atlanta, United States , Austin, United States and 165 more locations